Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
A South Korean pharmaceutical company developing drugs and biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug HM15275 enters Mid-Stage trial Results expected Jan 2027 (estimated)
- New obesity drug HM17321 enters first human safety trials Results expected Mar 2027 (estimated)
- New drug combo aims to shrink Hard-to-Treat tumors Results expected Aug 2027 (estimated)
-
New blood pressure drug aims for Round-the-Clock control
Disease control CompletedThis clinical trial is testing a new medication called HGP2102 for people with essential hypertension, or high blood pressure. The study compares HGP2102 to a control drug to see how well it lowers blood pressure over a full 24-hour period. Participants are adults with high blood…
Phase 3 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug HM15211 shows promise in reversing liver damage in NASH patients
Disease control CompletedThis study tests a new drug called HM15211 in 215 adults with NASH, a liver condition that can lead to scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver inflammation and scarring without making it worse…
Phase 2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New obesity drug aims for major weight loss in phase 3 trial
Disease control CompletedThis phase 3 study tests an investigational drug called HM11260C for weight loss in adults with obesity who do not have diabetes. Participants must have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with related health issues like high blood pressure. The tria…
Phase 3 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat stomach cancer
Disease control CompletedThis phase 2 study tested a new drug, FLX475, combined with the immunotherapy pembrolizumab (Keytruda) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors in patients who had already tried other treatments. The study…
Phase 2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New NSAID aims to match existing drug for back pain relief
Symptom relief CompletedThis completed Phase 3 study tested a new drug called HCP1004 against an existing painkiller (RLD2401) in 310 adults with chronic low-back pain lasting at least 3 months. The goal was to see if HCP1004 works just as well for pain and function, while monitoring safety. Participant…
Phase 3 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC